A pan-acting ligand like C4 may be useful in dealing with disease conditions where both Erk and CaMKII signaling pathways are altered, such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson’s disease (PD) [53,54,55,56]. Here, CAMK2G is linked to Parkinson disease.